DR Reddys Laboratories Ltd

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India

October 23, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Sub: Limited Review Reports of the Statutory Auditors on the Unaudited Financial Results for the quarter and half year ended September 30, 2026 with Unique Document Identification Number ("UDIN")

With reference to our earlier intimation on unaudited financial statements for the quarter and half-year ended September 30, 2026, filed with the stock exchanges today i.e. October 23, 2026, please find enclosed the Limited Review Reports of the Statutory Auditors thereon bearing the UDIN for your records. This is for your information and records.

Thanking you. Yours faithfully, For Dr. Reddy's Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Encl: as above

Deloitte Haskins & Sells LLP Chartered Accountants Meenakshi Pride Rock Tower Ill [Block - M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF DR. REDDY'S LABORATORIES LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Reddy's Laboratories Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and other comprehensive income/ (loss) of its associates and joint ventures for the quarter and half year ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the entities included in Appendix A.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Regd. Office: One International Center, Tower 3, 31stfloor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloltte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737

Deloitte Haskins & SellsLLP 6. The consolidated financial results of the Group for the quarter ended June 30, 2026, and quarter and half year ended September 30, 2025, included in the Statement, were reviewed by another auditor who expressed an unmodified conclusion on those statements on July 22, 2026, and October 24, 2025, respectively. The consolidated financial results for the year ended March 31, 2026, included in the Statement were audited by another auditor who expressed an unmodified opinion on the financial statement on May 12, 2026.

Our conclusion on the Statement is not modified in respect of this matter. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)

Vikas Bagaria Partner (Membership No. 060408) (UDIN: 26060408CABHEY4392) Place: Hyderabad Date: October 23, 2026

Deloitte Haskins & Sells LLP Appendix A: Results of the entities included in Statement Sno Particulars Remarks 1 Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. Subsidiary 2 Aurigene Oncology Limited Subsidiary 3 Aurigene Pharmaceutical Services Limited Subsidiary 4 beta Institute gemeinn ü tzige GmbH Subsidiary 5 betapharm Arzneimittel GmbH Subsidiary 6 Cheminor Employees Welfare Trust Other consolidating entity 7 Cheminor Investments Limited Subsidiary 8 Clean Renewable Energy KK 2A Private Limited Associate 9 Dr. Reddy's (Beijing) Pharmaceutical Co. Limited Subsidiary 10 Dr. Reddy's and Nestl é Health Science Limited Subsidiary 11 Dr. Reddy's Bio-Sciences Limited Subsidiary 12 Dr. Reddy's Employees ESOS Trust Other consolidating entity 13 Dr. Reddy's Farmaceutica Do Brasil Ltda. Subsidiary 14 Dr. Reddy's Finland Oy Subsidiary 15 Dr. Reddy's Formulations Limited Subsidiary 16 Dr. Reddy's Laboratories (Australia) Pty. Limited Subsidiary 17 Dr. Reddy's Laboratories (EU) Limited Subsidiary 18 Dr. Reddy's Laboratories (Proprietary) Limited Subsidiary 19 Dr. Reddy's Laboratories (Thailand) Limited Subsidiary 20 Dr. Reddy's Laboratories (UK) Limited Subsidiary 21 Dr. Reddy's Laboratories Canada, Inc. Subsidiary 22 Dr. Reddy's Laboratories Chile SPA Subsidiary 23 Dr. Reddy's Laboratories Inc. Subsidiary 24 Dr. Reddy's Laboratories Jamaica Limited Subsidiary 25 Dr. Reddy's Laboratories Japan KK Subsidiary 26 Dr. Reddy's Laboratories Kazakhstan LLP Subsidiary 27 Dr. Reddy's Laboratories LLC, Russia Subsidiary 28 Dr. Reddy's Laboratories LLC, Ukraine Subsidiary 29 Dr. Reddy's Laboratories Malaysia Sdn. Bhd. Subsidiary 30 Dr. Reddy's Laboratories New York, LLC Subsidiary 31 Dr. Reddy's Laboratories Philippines Inc. Subsidiary 32 Dr. Reddy's Laboratories Romania Srl Subsidiary 33 Dr. Reddy's Laboratories SA Subsidiary 34 Dr. Reddy's Laboratories SAS Subsidiary 35 Dr. Reddy's Laboratories Taiwan Limited Subsidiary

Deloitte Haskins & SellsLLP Sno Particulars Remarks 36 Dr. Reddy's New Zealand Limited Subsidiary 37 Dr. Reddy's Research Foundation Other consolidating entity 38 Dr. Reddy's Sri Subsidiary 39 Dr. Reddy's Denmark ApS Subsidiary 40 Dr. Reddy's Netherlands B.V. Subsidiary 41 DRES Energy Private Limited Joint venture 42 DRL Impex Limited Subsidiary 43 Idea2Enterprises (India) Pvt. Limited Subsidiary 44 Imperial Owners and Land Possessions Private Limited Subsidiary 45 Industrias Quimicas Falcon de Mexico, S.A. de CV Subsidiary 46 Kunshan Rotam Reddy Pharmaceutical Co. Limited (including Kunshan Rotam Reddy Medicine Comoany Limited) Joint venture 47 Lacock Holdings Limited Subsidiary 48 Nimbus Health GmbH Subsidiary 49 North Star OpCo Limited Subsidiary 50 North Star Sweden AB Subsidiary 51 Northstar Switzerland SARL Subsidiary 52 O2 Renewable Energy IX Private Limited Associate 53 Promius Pharma LLC Subsidiary 54 Reddy Holding GmbH Subsidiary 55 Reddy Netherlands B.V. Subsidiary 56 Reddy Pharma Iberia SAU Subsidiary 57 Reddy Pharma Italia SRL Subsidiary 58 Reddy Pharma SAS Subsidiary 59 Svaas Wellness Limited (ceased to be step subsidiary w.e.f April 7 2026) Subsidiary 60 Dr. Reddy's Laboratories (Vietnam) Company Limited effective from May 09, 2025 Subsidiary

Deloitte Haskins & Sells LLP Chartered Accountants Meenakshi Pride Rock Tower III [Block - M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy District Hyderabad-500032 Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF DR. REDDY'S LABORATORIES LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Dr. Reddy's Laboratories Limited ("the Company"), for the quarter and Half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Regd. Office: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 Page 1 of 2

Deloitte Haskins & Sells LLP 5. The standalone financial results of the Company for the quarter ended June, 30, 2026 and quarter and half year ended September 30, 2025 included in the Statement, were reviewed by another auditor who expressed an unmodified conclusion on those statements on July 22, 2026 and October 24, 2025 respectively. The Standalone financial results for the year ended March 31, 2026, included in the Statement were audited by another auditor who expressed an unmodified opinion on the financial statements on May 12, 2026.

Our conclusion on the Statement is not modified in respect of this matter. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)

Vikas Bagaria Partner (Membership No. 060408) (UDIN: 2606048XLHVUB4882) Place: Hyderabad Date: October 23, 2026 Page 2 of 2